Latest Breaking News On - Dr reddy institute of life sciences - Page 1 : comparemela.com

UoH, DRILS ink MoU for collaboration - The Hindu BusinessLine

UoH, DRILS ink MoU for collaboration - The Hindu BusinessLine
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

Andhra pradeshDevesh nigamDr reddy laboratories ltdUniversity of hyderabad uoSkill developmentDr reddy institute of life sciencesLife sciencesManaging directorLaboratories ltd

Centre of excellence on flow chemistry to come up in Hyderabad

The Telangana government on Thursday announced the setting up of a multi-industry supported innovation and technology hub for flow chemistry in Hyderabad, to ensure greater incorporation of its techniques during pharma R&D and greater .

Andhra pradeshUnited kingdomKt rama raoSrinivas orugantiSatyanarayana chavaShakthi nagappanJayesh ranjanLife sciences pharmaProf shu kobayashi university of tokyoProf goverdhan mehta university of hyderabadDr reddy laboratories ltdDr reddy laboratories ltd coProf oliver kappe university of grazProf steven ley university of cambridgeLife sciencesDr reddy institute of life sciences

UK strain more potent than its ancestor, say experts from around India

Updated Jan 11, 2021 | 10:44 IST UK strain will be more potent as compared to its ancestor that first affected people in China in December two years ago. UK strain more potent than its ancestor, say experts from around India | Photo Credit: IANS Hyderabad: The country’s researchers, including ones from Hyderabad, have found that the mutations in the fresh UK strain can be advantageous to Covid providing it more fitness. This means that UK strain will be more potent as compared to its ancestor that first affected people in China in December two years ago. The mutations in proteins can have major impact on viral transmission and host immune responses, according to the researchers.

Andhra pradeshUnited kingdomNew delhiJamia hamdardSeyede hasnainBioinception pvt ltd united kingdomNational institute of pathologyInstitute of molecular medicineDr reddy institute of life sciencesPhoto creditMolecular medicineNational instituteLife sciencesCorona strain in indiaIndian experts speak on uk strainHyderabad latest news

Experimental cancer drug with GLP-1 agonist can help control weight, manage glucose levels in diabetes patients

Experimental cancer drug with GLP-1 agonist can help control weight, manage glucose levels in diabetes patients GLP-1 analogues, also called incretin mimics, are a rather new class of injectable drugs that are given to patients with type 2 diabetes who can’t control their blood glucose levels with oral medications. Representational image. Pixabay A group of researchers at Dr Reddy’s Institute of Life Sciences, India, have found that an experimental cancer drug called MS-275, when used along with a class of diabetes drugs called Glucagon-like peptide 1 agonists or GLP-1 analogues help control blood glucose levels and weight loss in mice models of diabetes associated with obesity.

Prasenjit mitraDr reddy institute of life sciencesWorld health organisationLife sciencesபிரசேஞ்சித் மித்ராடாக்டர் சிவப்பு நிறுவனம் ஆஃப் வாழ்க்கை அறிவியல்உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்வாழ்க்கை அறிவியல்